Top

International Journal of Clinical Oncology

Published in:

01-04-2010 | Case Report

Erythrocytosis caused by erythropoietin-producing thymic carcinoma

Authors: Wataru Munakata, Kazuteru Ohashi, Koji Sakaguchi, Hirotoshi Horio, Tsunekazu Hishima, Hideki Akiyama, Hisashi Sakamaki

Published in: International Journal of Clinical Oncology | Issue 2/2010

Abstract

We describe the first reported case, in an 82-year-old man, of erythrocytosis caused by an erythropoietin (EPO)-producing thymic carcinoma. The patient underwent computed tomography-guided fine-needle aspiration of a 6-cm anterior mediastinal mass, and histological findings revealed thymic squamous cell carcinoma. The existence of EPO was confirmed immunohistochemically using the tumor tissue. Postoperative clinical improvement of erythrocytosis and the decline of EPO suggest a paraneoplastic nature of erythrocytosis as seen in this patient.

Hammond D, Winnick S (1974) Paraneoplastic erythrocytosis and ectopic erythropoietin. Ann N Y Acad Sci 230:219–227CrossRefPubMed

Samyn I, Fontaine C, Van Tussenbroek F et al (2004) Paraneoplastic syndromes in cancer: case 1. Polycythemia as a result of ectopic erythropoietin production in metastatic pancreatic carcinoid tumor. J Clin Oncol 22:2240–2242CrossRefPubMed

Marzo F, Lavorgna A, Coluzzi G et al (2008) Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 26:183–187CrossRefPubMed

Arcasoy MO (2005) Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 11:20–27PubMed

Newland AM, Black CD (2008) Tumor progression associated with erythropoiesis stimulating agents. Ann Pharmacother 42:1865–1870CrossRefPubMed

Noguchi Y, Goto T, Yufu Y et al (1999) Gene expression of erythropoietin in renal cell carcinoma. Intern Med 38:991–994CrossRefPubMed

Matsuyama M, Yamazaki O, Horii K et al (2000) Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. J Surg Oncol 75:197–202CrossRefPubMed

Miyoshi I, Saito T, Taguchi H et al (2004) Erythropoietin-producing cerebellar tumour. Br J Haematol 125:105CrossRefPubMed

Yokoyama Y, Shinohara A, Hirokawa M et al (2003) Erythrocytosis due to an erythropoietin-producing large uterine leiomyoma. Gynecol Obstet Invest 56:179–183CrossRefPubMed

10.

Bruneval P, Sassy C, Mayeux P et al (1993) Erythropoietin synthesis by tumor cells in a case of meningioma associated with erythrocytosis. Blood 81:1593–1597PubMed

11.

Vogel TW, Brouwers FM, Lubensky IA et al (2005) Differential expression of erythropoietin and its receptor in von Hippel-Lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. J Clin Endocrinol Metab 90:3747–3751CrossRefPubMed

12.

Kawai H, Kojima M, Yokota M et al (2000) Erythropoietin-producing pancreatic ductal adenocarcinoma. Pancreas 21:427–429CrossRefPubMed

13.

Bohnen RF, Banisadre M, Gulbrandson RN et al (1990) Erythrocytosis caused by an erythropoietin-producing breast adenocarcinoma. West J Med 152:417–418PubMed

14.

Miyoshi I, Uemura Y, Nakai T et al (2009) Erythropoietin-producing lung cancer. Intern Med 48:389–390CrossRefPubMed

15.

Matsuo M, Koga S, Kanetake H et al (2003) EPO-producing gastric carcinoma in a hemodialysis patient. Am J Kidney Dis 42:E3–E4CrossRefPubMed

16.

Wiesener MS, Seyfarth M, Warnecke C et al (2002) Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel–Lindau gene in a renal cell carcinoma. Blood 99:3562–3565CrossRefPubMed

17.

Bunn HF, Gu J, Huang LE et al (1998) Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 201:1197–1201PubMed

18.

Lacombe C, Mayeux P (1998) Biology of erythropoietin. Haematologica 83:724–732PubMed

Title: Erythrocytosis caused by erythropoietin-producing thymic carcinoma
Authors: Wataru Munakata
Kazuteru Ohashi
Koji Sakaguchi
Hirotoshi Horio
Tsunekazu Hishima
Hideki Akiyama
Hisashi Sakamaki
Publication date: 01-04-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0029-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan

Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone

Hepatosplenic αβ T cell lymphoma

18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer

Huge pedunculated angiomyofibroblastoma of the vulva

Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention

Keynote webinar | Spotlight on antibody–drug conjugates in cancer